For the quarter ending 2026-03-31, VYNE has $25,873K in assets. $1,236K in debts. $24,631K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 24,631 | 24,027 | 22,047 | |
| Investment in marketable securities | 297 | 4,981 | 17,600 | |
| Prepaid and other current assets | 861 | 1,002 | 4,696 | |
| Total current assets | 25,789 | 30,010 | 44,343 | |
| Property and equipment, net | 84 | 90 | 102 | |
| Operating lease right of use assets (note 9) | - | 0 | 32 | |
| Non-current prepaid expenses and other assets | 0 | 60 | 241 | |
| Total non-current assets | 84 | 150 | 375 | |
| Total assets | 25,873 | 30,160 | 44,718 | |
| Trade payables | 261 | 1,041 | 1,414 | |
| Other current liabilities | - | 0 | 0 | |
| Operating lease liabilities (note 9) | - | 0 | 25 | |
| Accrued expenses | 889 | 941 | 3,578 | |
| Employee-related obligations | 86 | 413 | 819 | |
| Total current liabilities | 1,236 | 2,395 | 5,836 | |
| Total liabilities | 1,236 | 2,395 | 5,836 | |
| Common stock 0.0001 par value 150,000,000 shares authorized at march 31, 2026 and december 31, 2025 and 33,352,858 and 33,323,171 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 3 | 3 | 2 | |
| Additional paid-in capital | 785,872 | 785,413 | 784,418 | |
| Accumulated other comprehensive income | 0 | 2 | -2 | |
| Accumulated deficit | -761,238 | -757,653 | -745,536 | |
| Total stockholders' equity | 24,637 | 27,765 | 38,882 | |
| Total liabilities and stockholders equity | 25,873 | 30,160 | 44,718 | |
VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. (VYNE)